ClinicalTrials.gg
RecruitingNCT04628663Updated Sep 30, 2025

Effects of Dexmedetomidine on Intraocular Pressure During Scheduled Spine Surgeries

An interventional study of Dexmedetomidine and Normal Saline in Intraocular Pressure, sponsored by Attikon Hospital. Recruiting at 1 site in Greece. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-09-30.

Sponsored by Attikon Hospital · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Mar 2021; still recruiting 5 years 7 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The aim of this study is to examine the effects of intraoperative systemic use of dexmedetomidine on the intraocular pressure (IOP) in patients undergoing spine surgeries in a prone position under general anesthesia.

Read the detailed description

The study is a Prospective, Randomized, Placebo -controlled, Double-Blinded clinical trial Adult patients with an ASA physical status of class I, II or III who are scheduled for an elective spine surgery in prone position under general anesthesia will be included in the study.

The patients will be randomized with closed envelope manner into two groups: the group of dexmedetomidine and the group of normal saline.

In the dexmedetomidine group (DEX group), bolus dose 1,0 μg/kg of dexmedetomidine will be administered in 10min before induction to anesthesia and 0,4-0,8 μg/kg/h of dexmedetomidine will be infused continuously until the end of the surgery.

In the saline group (placebo group), the same volume of saline will be administered in an identical way.

All study medication will be prepared by an independent anesthesiologist who is not associated in the study (who will hold the randomization codes until the end of the study).

All patients will receive the same type of anaesthesia (TIVA with propofol) and postoperative analgesia including paracetamol 1gr iv (4 times/day) and continuous wound infiltration with ropivacaine 0.2% 5ml/h for 48 postoperative hours.

Basic monitoring for the study includes:

ECG, Invasive and noninvasive blood pressure, Heart Rate, EtCO2, SpO2, Cardiac Output (CO), Stroke Volume (SV), Stroke Volume Variation (SVV), Patient State index (PSi), IOP, Urine output.

Measurements

The measurement of IOP will be conducted in both eyes with Icare PRO tonometer by an ophthalmologist who will not know in which group the patient is in the below predefined time points:

  • T1: before administration of the study drug
  • T2: after administration of the bolus dose of the study drug
  • T3: after tracheal intubation
  • T4: just before prone position
  • T5: just after prone position
  • T6: 30min after T5
  • T7: 60min after T6
  • T8: 120min after T7
  • T9: 180min after T8
  • T10: at the end of the surgery and the patient in supine position At the time of each tonometer reading the following data set is collected: MAP, heart rate, EtCO2, SpO2, CO, SV, SVV, urine output, Psi, IOP. Moreover OPP will be calculated as MAP minus IOP.
02

Conditions studied

  • Intraocular Pressure
03

In context

Lead sponsor

Attikon Hospital is the lead sponsor of 86 studies on the registry; 17 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients undergoing scheduled spine surgery performed in prone position under general anaesthesia

Exclusion criteria

Exclusion Criteria:

  • Patients who refuse to be a part of the study
  • Patients with previous eye surgery
  • Preexisting eye disease (e.g glaucoma)
  • Allergy to the study drug or any drug which is in the trial
  • Preoperative unstable hemodynamics
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    DEX group

    Dexmedetomidine given at a bolus dose of 1,0 μg/kg 10min before induction of anesthesia and then after as a continuous infusion 0,4-0,8 μg/kg/h until the end of the surgery.

    Drug: Dexmedetomidine

  • Placebo comparator
    Placebo group

    Normal saline given as a bolus dose 10min before induction of anesthesia and then after as a continuous infusion until the end of the surgery.

    Other: Normal Saline

Interventions

  • Administration

    Also known as: Dexmed

  • OtherNormal Saline

    Administration

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Intraocular pressure (IOP)

    The measurement of IOP will be conducted in both eyes with Icare PRO tonometer by an ophthalmologist at predefined time points

    Time frame: Up to 15 minutes after the end of operation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04628663
Lead sponsor
Attikon Hospital
Responsible party
Paraskevi Matsota (Prof of Anaesthesiology, Attikon Hospital) — Principal investigator
First posted
Nov 13, 2020
Start date
Mar 20, 2021
Primary completion
Nov 2025 (estimated)
Completion
May 2026 (estimated)
Last update
Sep 30, 2025

Study contacts

Paraskevi Matsota, Prof
Contact
matsota@yahoo.gr
6945544563
Paraskevi Matsota, Prof
study chair · 2nd Department of Anesthesiology, Attikon University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion